Inotuzumab Ozogamicin API is a pharmaceutical-grade CD22-directed antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia (ALL). It combines a humanized monoclonal antibody targeting CD22 with the potent cytotoxic agent calicheamicin, enabling selective delivery of the drug to malignant B cells.
After binding to CD22-expressing cells, the conjugate is internalized, releasing calicheamicin intracellularly. The cytotoxic payload induces DNA double-strand breaks, leading to apoptosis of cancer cells while minimizing exposure to healthy tissues.
Manufactured under WHO-GMP-certified biopharmaceutical facilities, our Inotuzumab Ozogamicin API is produced using advanced recombinant biotechnology and conjugation technologies to ensure exceptional purity, biological activity, stability, and batch-to-batch consistency. Every batch undergoes rigorous quality testing and is supplied with comprehensive regulatory documentation, including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and Product Specifications.
Inotuzumab Ozogamicin API is used in injectable biopharmaceutical formulations for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).
It binds to the CD22 antigen on B lymphocytes and delivers the cytotoxic agent calicheamicin directly into cancer cells, causing DNA damage and programmed cell death.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Inotuzumab Ozogamicin API in commercial quantities for pharmaceutical and biopharmaceutical manufacturing worldwide.
Get Bulk Quote via WhatsApp